Pembrolizumab for B-cell lymphomas relapsing after or refractory to CD19-directed CAR T-cell therapy. Chong EA, Alanio C, Svoboda J, Nasta SD, et al. Blood 2022;139:1026-1038.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Chong EA, Alanio C, Svoboda J, Nasta SD, et al. Pembrolizumab for B-cell lymphomas relapsing after or refractory to CD19-directed CAR T-cell therapy. Blood 2022;139:1026-1038.
PMID: 34496014